HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke

HCID 1978Erstellt: 1. November 2026

Acebutolol

N-(3-acetyl-4-(2-hydroxy-3-(isopropylaMino)propoxy)phenyl)butyraMide · Prent · Sectral · ACEBUTOLOL · Acebuprolol · Acebutololum · Acetobutolol · dl-Acebutolol

https://huagongshe.com/de/chemical/1978

Identifikatoren & physikalische Daten

CAS No.	37517-30-9
Summenformel	C18H28N2O4
Durchschnittliche Molmasse	336,4 g/mol
Monoisotopische Masse	336,20490738 g/mol
SMILES	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1
InChIKey	GOEMGAFJFRBGGG-UHFFFAOYSA-N
PubChem CID	1978
ChEMBL	CHEMBL642
ChEBI	CHEBI:2379
EC No.	253-539-0
DTXSID	DTXSID2048539
Lokaler Name	Acebutolol

Chemische & physikalische Eigenschaften

XLogP	1,7
Polarare Oberfläche (TPSA)	87,7
H-Brücken-Donoren	3
H-Brücken-Akzeptoren	5
Frei drehbare Bindungen	10
Schwere Atome	24
Formalladung	0
Komplexität	400
Arzneimittel	Pharmaceuticals
LogP (Verteilungskoeffizient)	1.71.71
Löslichkeit	1.72e-01 g/LDMF: 10 mg/mL,DMSO: 5 mg/mL,Ethanol: 5 mg/mL,PBS (pH 7.2): 0.3 mg/mL259 mg/L
Human Drugs	Breast FeedingLactationMilk, HumanAntihypertensive AgentsAdrenergic Beta-AntagonistsAntiarrhythmicsPharmaceuticals
Schmelzpunkt	136-138119 - 123 °C119-123°C
Physical Description	Solid
Dissociation Constants	9.529.67
Collision Cross Section	187.43 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]190.2 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
Siedepunkt	472.9°C (rough estimate)
Dichte	1.1748 (rough estimate)
Brechungsindex	1.5700 (estimate)
Lagerbedingungen	-20°C Freezer
Aggregatzustand	A solid
pKa (Säurekonstante)	pKa 9.40 (Uncertain)
Farbe	Crystals
CAS Datenbank	37517-30-9(CAS DataBase Reference)
NIST chemische Informationen	Acebutolol(37517-30-9)
EPA chemische Informationen	Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (37517-30-9)

Sicherheit & Vorschriften

GHS-Einstufung	H362 (100%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]P203, P260, P263, P264, P270, and P318 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Weitere Sicherheitsinformationen	IMAP assessments - Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (.+-.)-: Environment tier I assessment
Hazard Classes and Categories	Lact. (100%)
Hepatotoxicity	Acebutolol is associated with a low rate of mild-to-moderate elevations of serum aminotransferase levels during treatment. These enzyme elevations are usually asymptomatic and transient and resolve even with continuation of therapy. There have been few documented cases of clinically apparent, acute liver injury attributed to acebutolol. The time to onset of injury was typically between 1 and 6 weeks of starting. The pattern of liver enzyme elevations was usually hepatocellular with an acute hepatitis-like presentation, although some cases present with a mixed pattern of enzymes. Fever commonly accompanied the liver injury, but usually without rash and eosinophia. Acebutolol is known to induce autoantibodies such as antinuclear antibody in 10% to 30% of patients, some of whom develop a lupus-like syndrome with fatigue, skin rash and arthralgias. Serum enzyme elevations may accompany this syndrome, but jaundice and symptoms of liver injury are uncommon. The published cases of hepatotoxicity due to acebutolol were relatively mild, self-limited and recovery was rapid upon stopping. Rechallenge resulted in rapid recurrence of injury.
Drug Induced Liver Injury	Drug-Induced Liver Injury Severity and Toxicity (DILIst)acebutololDILI PositiveOralDOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation	◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals	Acebutolol4.719.7An optimal response is usually achieved with dosages of 400 to 800 mg per day, although some patients have been maintained on as little as 200 mg per day.

Anwendungen & Verwendung

Verwenden

Cardioselective adrenergic blocker. Antihypertensive; antianginal; antiarrhythmic (class II)

CAS No.

37517-30-9

Summenformel

C18H28N2O4

Durchschnittliche Molmasse

336,4 g/mol

Monoisotopische Masse

336,20490738 g/mol

SMILES

CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1

InChIKey

GOEMGAFJFRBGGG-UHFFFAOYSA-N

PubChem CID

1978

ChEMBL

CHEMBL642

ChEBI

CHEBI:2379

EC No.

253-539-0

DTXSID

DTXSID2048539

Lokaler Name

Acebutolol

Chemische & physikalische Eigenschaften

XLogP

1,7

Polarare Oberfläche (TPSA)

87,7

H-Brücken-Donoren

H-Brücken-Akzeptoren

Frei drehbare Bindungen

Schwere Atome

Formalladung

Komplexität

400

Arzneimittel

Pharmaceuticals

LogP (Verteilungskoeffizient)

1.71.71

Löslichkeit

1.72e-01 g/LDMF: 10 mg/mL,DMSO: 5 mg/mL,Ethanol: 5 mg/mL,PBS (pH 7.2): 0.3 mg/mL259 mg/L

Human Drugs

Breast FeedingLactationMilk, HumanAntihypertensive AgentsAdrenergic Beta-AntagonistsAntiarrhythmicsPharmaceuticals

Schmelzpunkt

136-138119 - 123 °C119-123°C

Physical Description

Solid

Dissociation Constants

9.529.67

Collision Cross Section

187.43 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]190.2 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]

Siedepunkt

472.9°C (rough estimate)

Dichte

1.1748 (rough estimate)

Brechungsindex

1.5700 (estimate)

Lagerbedingungen

-20°C Freezer

Aggregatzustand

A solid

pKa (Säurekonstante)

pKa 9.40 (Uncertain)

Farbe

Crystals

CAS Datenbank

37517-30-9(CAS DataBase Reference)

NIST chemische Informationen

Acebutolol(37517-30-9)

EPA chemische Informationen

Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (37517-30-9)

Sicherheit & Vorschriften

GHS-Einstufung

H362 (100%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]P203, P260, P263, P264, P270, and P318 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Weitere Sicherheitsinformationen

IMAP assessments - Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (.+-.)-: Environment tier I assessment

Hazard Classes and Categories

Lact. (100%)

Hepatotoxicity

Acebutolol is associated with a low rate of mild-to-moderate elevations of serum aminotransferase levels during treatment. These enzyme elevations are usually asymptomatic and transient and resolve even with continuation of therapy. There have been few documented cases of clinically apparent, acute liver injury attributed to acebutolol. The time to onset of injury was typically between 1 and 6 weeks of starting. The pattern of liver enzyme elevations was usually hepatocellular with an acute hepatitis-like presentation, although some cases present with a mixed pattern of enzymes. Fever commonly accompanied the liver injury, but usually without rash and eosinophia. Acebutolol is known to induce autoantibodies such as antinuclear antibody in 10% to 30% of patients, some of whom develop a lupus-like syndrome with fatigue, skin rash and arthralgias. Serum enzyme elevations may accompany this syndrome, but jaundice and symptoms of liver injury are uncommon. The published cases of hepatotoxicity due to acebutolol were relatively mild, self-limited and recovery was rapid upon stopping. Rechallenge resulted in rapid recurrence of injury.

Drug Induced Liver Injury

Drug-Induced Liver Injury Severity and Toxicity (DILIst)acebutololDILI PositiveOralDOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation

◉ Summary of Use during Lactation

EPA Human Health Benchmarks for Pharmaceuticals

Acebutolol4.719.7An optimal response is usually achieved with dosages of 400 to 800 mg per day, although some patients have been maintained on as little as 200 mg per day.